Research and innovation
R&D Overview
Developing proprietary advanced therapeutics for complex diseases
We focus on therapeutic cancer vaccines for solid tumors and exosome-based therapeutics. Leveraging AI-driven technologies, we conduct neoantigen screening and validation, dendritic cell engineering, exosome research, and quality development systems. Through collaboration with clinical and research partners, we accelerate the translation of innovative therapies toward clinical applications.
Therapeutic Vaccines for Solid Tumors
Advancing personalized immunotherapy for hard-to-treat solid tumors
Our research integrates personalized neoantigen screening and validation with dendritic cell therapy to address the heterogeneity of challenging solid tumors.
Ovarian cancerPancreatic cancerProstate cancerGlioblastoma
Innovative Exosome Therapeutics
Local delivery and multi-mechanism approaches for innovative exosome therapeutics
Dry eyePharyngeal and airway hyperresponsivenessAllergic rhinitisMigraine
Science and Technology Platforms
Platform capabilities supporting critical R&D activities
From neoantigen screening to dendritic cell and exosome research, we continuously advance our methodologies, development processes, and quality systems.